查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984179

自然杀手细胞疗法市场：2026-2032年全球市场预测（按治疗方法、细胞来源、应用和最终用户划分）

Natural Killer Cell Therapeutics Market by Therapy Type, Cell Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自然杀手细胞疗法市场价值将达到 5.3335 亿美元，到 2026 年将成长至 5.7111 亿美元，到 2032 年将达到 8.7226 亿美元，年复合成长率为 7.27%。

主要市场统计数据
基准年 2025 5.3335亿美元
预计年份：2026年 5.7111亿美元
预测年份 2032 8.7226亿美元
复合年增长率 (%) 7.27%

为自然杀手细胞疗法提供了一个清晰权威的框架，重点介绍了科学进展、营运挑战以及相关人员面临的策略挑战。

自然杀手 (NK) 细胞疗法是免疫学、细胞工程和临床肿瘤学的精彩融合，其发展得益于 NK 细胞固有的细胞毒性以及基因和生产技术的进步。该领域已从 NK 细胞生物学的基础发现发展成为拥有多元化治疗方案的研发管线，这些方案优先考虑安全性、即用性和克服肿瘤免疫逃脱的能力。基因编辑、细胞增殖平台以及与查核点抑制剂和标靶治疗联合应用的策略的进步，已显着拓展了治疗范围，使其从血液系统疾病扩展到固态肿瘤和自体免疫疾病。

本报告全面概​​述了正在重塑自然杀手细胞疗法开发和交付的技术、监管和商业性转折点。

自然杀手细胞疗法的前景经历了几个关键转折点，这些转折点从根本上改变了研发路径和商业性决策。诸如先进的基因编辑工具、稳健的NK细胞株的出现以及可扩展的无饲养层增殖系统等技术进步，显着提高了生产稳定高效细胞疗法的潜力。同时，生物标记和影像技术的进步使得对标靶活性和持久性的评估能够更早、更客观，从而为临床应用制定更有效率的决策和患者选择策略。

对 2025 年关税措施如何重塑细胞治疗计画的供应链、製造决策和合作协定实践进行基于证据的分析。

2025年关税的实施对整个细胞治疗价值链造成了多方面的压力，影响了原物料采购、资本设备购买和跨国合作。依赖进口试剂、专用耗材和一次性生物反应器组件的製造商面临更高的收货成本和更长的前置作业时间，因此更加重视供应商资格合格和风险缓解策略。许多机构已透过供应商多元化、认证替代供应商以及尽可能加快在地采购倡议来应对，以降低关税波动带来的风险。

综合細項分析揭示了产品类型、治疗适应症、细胞来源和最终用户趋势如何全面决定发展路径和市场定位。

在基于类型的细分中，同种异体移植和自体移植方法之间存在差异，这具有重要的营运和策略意义。同种异体移植产品优先考虑即时可用性和通用捐赠者结构，以实现快速给药和简化物流。在此领域，现成产品形式正被优化以提高多剂量稳定性和广泛的HLA相容性，而通用供体策略则优先考虑降低宿主抗移植物反应的基因修饰。自体的研发继续强调个人化治疗的特点；个人化生产增强了免疫相容性，但需要客製化的生产流程和针对特定患者的治疗时间管理。

一份区域比较评估报告，详细介绍了影响美洲、欧洲、中东和非洲以及亚太地区战略选择的临床、製造和监管因素。

在美洲，临床试验和转化研究的基础设施集中在杰出的研究中心，这些中心将学术专长与产业伙伴关係相结合。该地区受益于先进的製造网络、强大的合约研究组织（CDO）基础以及充满活力的投资者群体，这些都为后期研发提供了支持。该地区的监管机构也在製定细胞衍生产品的监管框架，这有助于开发商与监管机构之间的早期合作，并确保监管策略和证据要求的一致性。

深入剖析各公司如何透过技术平台、卓越製造和协作经营模式。

在整个产业中，各公司在多个方面展现出差异化优势，包括转化研究的深度、生产平台的实力以及整合伴随诊断和联合治疗的能力。拥有自主工程平台的生物技术公司专注于验证独特的作用机制和可扩展的生产工艺，而整合型製药合作伙伴则提供后期研发能力、全球监管合规经验和商业化基础设施。早期投资于疗效检测方法开发和完善品管系统的公司，往往更有信心应对临床开发的关键节点，因为他们能够预判监管机构的问询，并证明不同批次产品的一致性。

为领导者提供关键策略指导，以协调检测方法、建立强大的生产系统，并建立伙伴关係，从而加速临床部署和支付方协议。

行业领导者应优先考虑儘早使分析和功效检测与监管要求保持一致，以减少后续环节的延误并建立引人注目的产品特性。投资于标准化的放行标准和正交功能性引线，可简化与製程变更相关的对比评估。同时，各组织应评估混合生产策略，将复杂製程的集中式专业知识与区域灌装和包装能力结合，以优化产品上市时间并降低贸易政策风险。

采用透明的跨学科调查方法，结合与专家的直接对话、文献整合和迭代检验，为细胞治疗领域的相关人员提供可操作的见解。

本分析整合了多种证据来源，以确保对该领域进行全面且多角度的观点。关键资料来源包括对参与细胞疗法开发的临床研究人员、生产专家和营运经理进行的结构化访谈。此外，还透过查阅同行评审文献、公开的监管指南和临床试验註册数据，追踪了转化研究的进展。技术评估则对细胞製备方法、工程平台和生物製程技术进行了评估，以确定其相对操作复杂性和成熟度。

该框架简洁地整合了科学预期和营运挑战，并展示了相关人员应如何协调开发、製造和商业化以实现对患者的影响。

自然杀手细胞疗法正处于一个十字路口，科学有效性与决定临床和商业性成功的运作及监管现实相互交织。儘管细胞工程、来源标准化和转化科学的进步推动了该领域的发展，但要实现持续的临床影响，还需要在生产稳健性、检测标准化和相关人员参与方面取得同步进展。卓越的组织会将严谨的科学差异化与规范的流程管理结合，并积极应对供应链和监管方面的复杂性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 自然杀手细胞疗法市场：依治疗方法划分

  • 同种异体NK细胞疗法
  • 自体NK细胞疗法
  • CAR-NK细胞疗法
  • NK细胞活化生技药品
  • 细胞激素诱导的NK细胞疗法

第九章 自然杀手细胞疗法市场：依细胞来源划分

  • 细胞株
    • KHYG-1
    • NK-92
  • 诱导性多功能干细胞
  • 週边血
  • 脐带血

第十章 自然杀手细胞疗法市场：依应用领域划分

  • 自体免疫疾病
  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 感染疾病
  • 固体癌
    • 乳癌
    • 肺癌
    • 卵巢癌

第十一章 自然杀手细胞疗法市场：以最终用户划分

  • 研究机构
  • 医院
  • 专科诊所

第十二章 自然杀手细胞疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 自然杀手细胞疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 自然杀手细胞疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国自然杀手细胞疗法市场

第十六章：中国自然杀手细胞疗法市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Nektar Therapeutics
  • ImmunityBio, Inc. by NantWorks LLC
  • Nkarta, Inc.
  • Takeda Pharmaceutical Company Limited
  • Century Therapeutics, Inc.
  • Celularity Inc.
  • Merck KGaA
  • BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
  • Sanofi SA
  • Innate Pharma SA
  • Cytovia Therapeutics, Inc.
  • Fate Therapeutics, Inc.
  • Fortress Biotech, Inc.
  • Acepodia Inc.
  • Affimed NV
  • Agenus Inc.
  • Cytovac A/S
  • Dragonfly Therapeutics, Inc.
  • Emercell SAS by Onward Therapeutics SA
  • Gamida Cell Ltd. by Ayrmid Ltd.
  • Glycostem Therapeutics BV
  • iCell Gene Therapeutics LLC
  • Multimmune GmbH
  • PersonGen BioTherapeutics
  • Phio Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
Product Code: MRR-5C6F41F5AFEC

The Natural Killer Cell Therapeutics Market was valued at USD 533.35 million in 2025 and is projected to grow to USD 571.11 million in 2026, with a CAGR of 7.27%, reaching USD 872.26 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 533.35 million
Estimated Year [2026] USD 571.11 million
Forecast Year [2032] USD 872.26 million
CAGR (%) 7.27%

A clear and authoritative framing of natural killer cell therapeutics highlighting scientific momentum, operational hurdles, and strategic imperatives for stakeholders

Natural killer cell therapeutics represent a compelling convergence of immunology, cell engineering, and clinical oncology, driven by the innate cytotoxic capacity of NK cells and growing mastery of genetic and manufacturing technologies. The field has matured from fundamental discoveries about NK cell biology into a pipeline of diverse therapeutic approaches that prioritize safety, off-the-shelf convenience, and the capacity to address tumor immune evasion. Progress in gene editing, cell expansion platforms, and combination strategies with checkpoint inhibitors or targeted agents has materially expanded the therapeutic hypothesis beyond hematological indications into solid tumors and autoimmune applications.

Despite clear scientific rationale and encouraging early-stage clinical signals, the pathway to broad clinical adoption remains conditional on several factors. Manufacturing reproducibility, product consistency, and scalable logistics must be reconciled with regulatory expectations that emphasize cell character, potency assays, and long-term safety monitoring. Collaboration between academic centers, specialized contract development and manufacturing organizations, and industry partners has been essential to translate bench advances into clinical-grade products. As clinical programs proliferate, precise differentiators such as source material selection, degree of donor matching, and the use of engineered receptors will increasingly determine clinical positioning and value creation.

This introduction situates stakeholders to evaluate opportunities and risks across development, commercialization, and policy landscapes while underscoring the imperative for integrated strategies that bridge biological innovation with operational excellence.

A comprehensive synthesis of technological, regulatory, and commercial inflection points that are reshaping how natural killer cell therapeutics will be developed and delivered

The landscape of natural killer cell therapeutics has experienced several pivotal shifts that collectively alter development pathways and commercial calculus. Technological advances such as refined gene editing tools, the emergence of robust NK cell lines, and scalable feeder-free expansion systems have materially improved the feasibility of producing consistent, potent cell products. Parallel progress in biomarkers and imaging is enabling earlier, more objective assessments of on-target activity and persistence, which in turn streamlines translational decision-making and patient selection strategies.

Regulatory engagement has likewise evolved from ad hoc developer interactions to more systematic frameworks focused on control strategies, comparability, and post-approval evidence generation. Regulators are signalling expectations for integrated control plans that encompass raw material traceability, release assays that capture functional potency, and risk-based safety monitoring. These expectations are encouraging companies to invest earlier in standardized assay development and to seek harmonized dialogue with authorities to mitigate delays.

Commercially, the market structure is shifting toward partnerships that combine clinical expertise, manufacturing capacity, and global market access. The economics of production and distribution have prompted experimentation with novel commercial models, including regionalized manufacturing networks and service-based supply arrangements. Taken together, these trends are remapping the competitive landscape, accelerating consolidation of development expertise, and redefining success metrics beyond traditional efficacy endpoints to include manufacturability, speed to clinic, and payor engagement strategies.

An evidence-based analysis of how 2025 tariff measures have reshaped supply chains, manufacturing decisions, and collaborative contracting practices across cell therapy programs

The imposition of tariffs in 2025 exerted multidimensional pressures across the cell therapy value chain, influencing raw material sourcing, capital equipment acquisition, and cross-border collaborations. Manufacturers reliant on imported reagents, specialized consumables, and single-use bioreactor components experienced elevated landed costs and extended lead times, which in turn increased the emphasis on supplier qualification and risk mitigation strategies. Many organizations responded by diversifying supplier portfolios, qualifying secondary vendors, and accelerating local sourcing initiatives where feasible to reduce exposure to tariff-related volatility.

Capital-intensive investments in automation and closed-system manufacturing were reprioritized as procurement timelines became less predictable; organizations that had previously depended on just-in-time delivery models found it necessary to build buffer inventories or lease redundant equipment to maintain clinical timelines. The tariff environment also influenced decisions about where to locate clinical manufacturing capacity, prompting greater consideration of nearshoring options and regionally distributed production hubs that can insulate programs from trade policy shifts.

On the collaboration front, cross-border academic and industry consortia adapted contractual terms to account for tariff risk, including revised pricing schedules and shared inventory strategies. Regulatory dossiers and quality agreements were updated to reflect alternative supply chains and to document equivalence between original and substitute materials. While the tariffs did not alter the fundamental science, they did raise the transactional complexity of bringing cell therapies to clinic, thereby favoring organizations with integrated supply chain capabilities and adaptive procurement practices.

Integrated segmentation analysis unveiling how product type, therapeutic indication, cellular source, and end-user dynamics collectively determine development pathways and commercial positioning

Type-based segmentation highlights a bifurcation between allogeneic and autologous approaches with meaningful operational and strategic implications. Allogeneic offerings emphasize off-the-shelf availability and the pursuit of universal donor constructs to enable rapid administration and simplified logistics; within that domain, off-the-shelf product formats are being optimized for multi-dose stability and broad HLA compatibility, while universal donor strategies prioritize genetic modifications that reduce host-versus-graft interactions. Autologous development continues to stress personalized therapy attributes, where individualized production affords closer immunologic matching but requires bespoke manufacturing workflows and patient-specific timeline management.

Indication-driven segmentation clarifies differential therapeutic pressures across autoimmune disease, hematological malignancies, infectious disease, and solid tumors. Hematological malignancies remain a focal point with subtypes such as leukemia, lymphoma, and multiple myeloma demonstrating distinct response dynamics and differing requirements for cellular persistence and trafficking. Solid tumor efforts, exemplified by work in breast, lung, and ovarian cancers, confront microenvironmental barriers and antigen heterogeneity, driving investment in combination regimens and engineering solutions that enhance tumor infiltration. Autoimmune and infectious disease indications are prompting exploration of modulatory NK cell strategies that balance cytotoxicity with immunoregulatory functions.

Source selection plays a defining role in product characteristics, with cell line-derived products and induced pluripotent stem cell approaches offering scalable, standardized inputs. Peripheral blood and umbilical cord blood sources continue to provide clinically validated starting points that influence donor variability, expansion kinetics, and regulatory documentation. Within cell line approaches, specific platforms are being leveraged for their reproducibility and amenability to genetic modification, which accelerates construct iteration and process validation.

End-user segmentation reveals operational differentials across contract research and development organizations, hospitals and clinics, and research organizations. Hospitals and clinics-spanning academic research hospitals and specialized cancer centers-are central to early clinical translation and patient access, while contract research organizations and research organizations provide specialized capabilities in process development, trial execution, and translational science. These distinctions inform commercialization strategies, partnership models, and investment priorities across the ecosystem.

A comparative regional assessment detailing clinical, manufacturing, and regulatory factors across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive strategic choices

In the Americas, clinical trial activity and translational research infrastructure are concentrated in centers of excellence that combine academic expertise with industry partnerships. This region benefits from advanced manufacturing networks, a deep base of contract development organizations, and active investor communities that support later-stage development. Regulatory agencies in the region are also advancing frameworks for cell-based products, which encourages early engagement between developers and authorities to align on control strategies and evidence requirements.

Europe, Middle East & Africa present a heterogeneous environment where centers of scientific excellence coexist with diverse regulatory pathways and reimbursement ecosystems. Several countries have built targeted incentives and specialized facilities to attract cell therapy manufacturing, while cross-border trial networks facilitate patient recruitment for rare indications. Policy dialogues on access and pricing are shaping commercial approaches, and developers often tailor regional strategies to accommodate differing approval timelines and health technology assessment processes.

Asia-Pacific is characterized by rapid capacity expansion in manufacturing, strong public and private investment in biotech infrastructure, and active participation in global clinical development programs. Multiple jurisdictions are streamlining regulatory pathways to foster innovation while balancing safety oversight, and regional manufacturing hubs are being developed to serve both local populations and export markets. Across these geographies, strategic partnerships and local regulatory expertise are essential to navigate country-specific requirements and to scale production cost-effectively.

An incisive overview of how companies are differentiating through technical platforms, manufacturing excellence, and collaborative business models to capture therapeutic value

Across the landscape, companies are differentiating along several axes including depth of translational expertise, strength of manufacturing platforms, and ability to integrate companion diagnostics and combination regimens. Biotechs with proprietary engineering platforms focus on demonstrating distinct mechanisms of action and scalable production processes, whereas integrated pharmaceutical partners bring late-stage development capability, global regulatory experience, and commercialization infrastructure. Companies that invest early in potency assay development and robust quality systems tend to reach clinical inflection points more reliably because they can anticipate regulatory queries and demonstrate consistency across manufacturing runs.

Strategic alliances and licensing activities are commonplace, reflecting the need to combine scientific innovation with manufacturing scale and market access. Organizations that offer contract development and manufacturing services have become pivotal ecosystem enablers by providing modular capacity and technical expertise that reduce the barrier to clinic for smaller developers. Academic spinouts and research organizations continue to be critical sources of novel biology and translational proof-of-concept, often partnering with industry to de-risk initial clinical stages.

Competitive positioning is increasingly influenced by an entity's capacity to orchestrate multi-partner value chains, to protect intellectual property in key engineering domains, and to demonstrate clinical differentiation through biomarker-driven patient selection. The most successful companies blend scientific rigor with operational discipline and clear commercialization pathways.

Focused strategic guidance for leaders to harmonize assays, deploy resilient manufacturing, and forge partnerships that accelerate clinical adoption and payer alignment

Industry leaders should prioritize early harmonization of analytical and potency assays with regulatory expectations to reduce downstream delays and to build a defensible product profile. Investing in standardized release criteria and orthogonal functional readouts will streamline comparability assessments across process changes. Concurrently, organizations should evaluate hybrid manufacturing strategies that combine centralized expertise for complex steps with regional fill-and-finish capacity to optimize time to patient and to mitigate trade-policy exposure.

Strategic partnerships merit focused attention: pairing engineering-focused developers with organizations that provide clinical development scale and payer engagement expertise accelerates path-to-market and enhances reimbursement preparedness. Leaders should also embed translational biomarker programs within clinical development to refine patient selection, to rationalize combination strategies, and to demonstrate differential benefit versus competitors. Operationally, building resilient supply chains through dual-sourcing, buffer inventories for critical inputs, and qualified secondary suppliers reduces vulnerability to external disruptions.

Finally, engagement with payers, clinicians, and patient advocacy groups early in development will clarify value propositions and inform evidence generation plans that support adoption. Leaders that adopt an integrated approach-combining rigorous science, flexible manufacturing, and stakeholder-centric evidence strategies-will be best positioned to translate promising clinical signals into sustainable patient impact.

A transparent and multidisciplinary methodology combining primary expert engagement, literature synthesis, and iterative validation to derive actionable insights for cell therapy stakeholders

The analysis synthesizes diverse sources of evidence to ensure a robust, multi-perspective view of the field. Primary inputs included structured interviews with clinical investigators, manufacturing experts, and operational leaders engaged in cell therapy development, complemented by reviews of peer-reviewed literature, publicly available regulatory guidance, and clinical trial registries to track translational progress. Technology assessments evaluated cell sourcing methods, engineering platforms, and bioprocess modalities to determine their relative operational complexity and maturity.

Qualitative synthesis methods were used to triangulate findings across disparate data types, and comparative case analysis clarified how specific strategic choices map to operational outcomes. Validation was achieved through iterative expert review cycles, which provided critical challenge and refinement, especially around topics such as assay development, supply chain resilience, and regional regulatory nuance. Throughout, emphasis was placed on transparency of assumptions and on documenting the provenance of key inferences to facilitate follow-up inquiries or bespoke analyses.

This methodological approach balances depth with practical relevance, enabling stakeholders to understand not only what is changing in the field but why those changes matter for development, manufacturing, and commercialization decisions.

A concise synthesis of scientific promise and operational imperatives that frames how stakeholders must align development, manufacturing, and commercialization to achieve patient impact

Natural killer cell therapeutics occupy an inflection point where scientific plausibility intersects with operational and regulatory realities that will determine clinical and commercial success. The field's momentum is underpinned by advances in cell engineering, source standardization, and translational science, yet achieving durable clinical impact requires parallel progress in manufacturing robustness, assay standardization, and stakeholder engagement. Organizations that excel will be those that integrate rigorous scientific differentiation with disciplined process control, and that proactively address supply chain and regulatory complexity.

Effective translation will also hinge on pragmatic decisions about target indications, patient selection, and combination paradigms that reflect the unique biology of NK cells. Equally important are collaborative models that leverage specialized manufacturing partners and clinical networks to accelerate access while distributing risk. By aligning technical choices with operational capacity and market realities, developers and partners can convert promising clinical signals into accessible therapies that meet unmet patient needs.

In short, the pathway forward is both scientifically exciting and operationally demanding; success will require not only novel biology but also strategic execution across development, manufacturing, and commercialization functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Natural Killer Cell Therapeutics Market, by Therapy Type

  • 8.1. Allogeneic NK Cell Therapy
  • 8.2. Autologous NK Cell Therapy
  • 8.3. CAR-NK Cell Therapy
  • 8.4. NK Cell Engager Biologics
  • 8.5. Cytokine-Induced NK Cell Therapy

9. Natural Killer Cell Therapeutics Market, by Cell Source

  • 9.1. Cell Line
    • 9.1.1. KHYG-1
    • 9.1.2. NK-92
  • 9.2. Induced Pluripotent Stem Cells
  • 9.3. Peripheral Blood
  • 9.4. Umbilical Cord Blood

10. Natural Killer Cell Therapeutics Market, by Application

  • 10.1. Autoimmune Disease
  • 10.2. Hematological Malignancies
    • 10.2.1. Leukemia
    • 10.2.2. Lymphoma
    • 10.2.3. Multiple Myeloma
  • 10.3. Infectious Disease
  • 10.4. Solid Tumors
    • 10.4.1. Breast Cancer
    • 10.4.2. Lung Cancer
    • 10.4.3. Ovarian Cancer

11. Natural Killer Cell Therapeutics Market, by End User

  • 11.1. Research Organizations
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Natural Killer Cell Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Natural Killer Cell Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Natural Killer Cell Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Natural Killer Cell Therapeutics Market

16. China Natural Killer Cell Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Nektar Therapeutics
  • 17.6. ImmunityBio, Inc. by NantWorks LLC
  • 17.7. Nkarta, Inc.
  • 17.8. Takeda Pharmaceutical Company Limited
  • 17.9. Century Therapeutics, Inc.
  • 17.10. Celularity Inc.
  • 17.11. Merck KGaA
  • 17.12. BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
  • 17.13. Sanofi S.A.
  • 17.14. Innate Pharma S.A.
  • 17.15. Cytovia Therapeutics, Inc.
  • 17.16. Fate Therapeutics, Inc.
  • 17.17. Fortress Biotech, Inc.
  • 17.18. Acepodia Inc.
  • 17.19. Affimed N.V.
  • 17.20. Agenus Inc.
  • 17.21. Cytovac A/S
  • 17.22. Dragonfly Therapeutics, Inc.
  • 17.23. Emercell SAS by Onward Therapeutics SA
  • 17.24. Gamida Cell Ltd. by Ayrmid Ltd.
  • 17.25. Glycostem Therapeutics B.V.
  • 17.26. iCell Gene Therapeutics LLC
  • 17.27. Multimmune GmbH
  • 17.28. PersonGen BioTherapeutics
  • 17.29. Phio Pharmaceuticals Inc.
  • 17.30. Regeneron Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ALLOGENEIC NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ALLOGENEIC NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ALLOGENEIC NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOLOGOUS NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOLOGOUS NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOLOGOUS NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CAR-NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CAR-NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CAR-NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL ENGAGER BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL ENGAGER BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL ENGAGER BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CYTOKINE-INDUCED NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CYTOKINE-INDUCED NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CYTOKINE-INDUCED NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY KHYG-1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY KHYG-1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY KHYG-1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK-92, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK-92, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK-92, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 161. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 185. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 193. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)